The convergence of cancer prevention and therapy in early-phase clinical drug development

Cancer Cell

Volumn 6, Issue 4, 2004, Pages 321-326

  Abbruzzese, James L ^a   Lippman, Scott M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GEFITINIB; IMATINIB; NONSTEROID ANTIINFLAMMATORY AGENT;

ADVANCED CANCER; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INHIBITION; CANCER PREVENTION; CANCER RISK; CLINICAL TRIAL; COLON POLYPOSIS; COLORECTAL CARCINOMA; CYTOSTASIS; CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; GASTROINTESTINAL STROMAL TUMOR; GENETIC REGULATION; HIGH RISK PATIENT; HUMAN; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MOLECULAR BIOLOGY; MOUTH CARCINOMA; NEOPLASM; PRECANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; TECHNOLOGY; TREATMENT INDICATION;

EID: 5444275938     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2004.09.021     Document Type: Note

References (63)

1. Albanell J., Rojo F., Averbuch S., Feyereislova A., Mascaro J.M., Herbst R., LoRusso P., Rischin D., Sauleda S., Gee J., et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients. Histopathologic and molecular consequences of receptor inhibition J. Clin. Oncol. 20:2002;110-124
2. Altorki N.K., Keresztes R.S., Port J.L., Libby D.M., Korst R.J., Flieder D.B., Ferrara C.A., Yankelevitz D.F., Subbaramaiah K., Pasmantier M.W., et al. Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J. Clin. Oncol. 21:2003;2645-2650
3. Assersohn L., Salter J., Powles T.J., A'hern R., Makris A., Gregory R.K., Chang J., Dowsett M. Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer. Breast Cancer Res. Treat. 82:2003;113-123
4. Baron J.A., Cole B.F., Sandler R.S., Haile R.W., Ahnen D., Bresalier R., McKeown-Eyssen G., Summers R.W., Rothstein R., Burke C.A., et al. A randomized trial of aspirin to prevent colorectal adenomas. N. Engl. J. Med. 348:2003;891-899
5. Bernards R., Weinberg R.A. A progression puzzle. Nature. 418:2002;823
6. Bishop J.M., Weinberg R.A. Molecular Oncology. 1996;Scientific American, Inc, New York
7. Boon E.M., Keller J.J., Wormhoudt T.A., Giardiello F.M., Offerhaus G.J., van der Neut R., Pals S.T. Sulindac targets nuclear beta-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines. Br. J. Cancer. 90:2004;224-229
8. Boulay A., Zumstein-Mecker S., Stephan C., Beuvink I., Zilbermann F., Haller R., Tobler S., Heusser C., O'Reilly T., Stolz B., et al. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res. 64:2004;252-261
9. Califano J., van der Riet P., Westra W., Nawroz H., Clayman G., Piantadosi S., Corio R., Lee D., Greenberg B., Koch W., et al. Genetic progression model for head and neck cancer. Implications for field cancerization Cancer Res. 56:1996;2488-2492
10. Cheng L., Lai M.D. Aberrant crypt foci as microscopic precursors of colorectal cancer. World J. Gastroenterol. 9:2003;2642-2649
11. Clayman G.L., el-Naggar A.K., Lippman S.M., Henderson Y.C., Frederick M., Merritt J.A., Zumstein L.A., Timmons T.M., Liu T.J., Ginsberg L., et al. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J. Clin. Oncol. 16:1998;2221-2232
12. Cohen E.E., Rosen F., Stadler W.M., Recant W., Stenson K., Huo D., Vokes E.E. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol. 21:2003;1980-1987
13. Corless C.L., McGreevey L., Haley A., Town A., Heinrich M.C. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am. J. Pathol. 160:2002;1567-1572
14. Dannenberg A.J., Subbaramaiah K. Targeting cyclooxygenase-2 in human neoplasia. Rationale and promise Cancer Cell. 4:2003;431-436
15. Dannenberg A.J., Lippman S.M., Mann J.R., Subbaramaiah K., DuBois R.N. COX-2 and egfr. Pharmacological targets for chemoprevention J. Clin. Oncol. in press:2004
16. Dunn, B.K., Wickerham, D.L., and Ford, L.G. (2004). Prevention of hormone-related cancers: Breast cancer. J. Clin. Oncol., in press.
17. Eisenhauer E.A., O'Dwyer P.J., Christian M., Humphrey J.S. Phase I clinical trial design in cancer drug development. J. Clin. Oncol. 18:2000;684-692
18. Giardiello F.M., Hamilton S.R., Krush A.J., Piantadosi S., Hylind L.M., Celano P., Booker S.V., Robinson C.R., Offerhaus G.J. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med. 328:1993;1313-1316
19. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell. 100:2000;57-70
20. He T.C., Chan T.A., Vogelstein B., Kinzler K.W. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell. 99:1999;335-345
21. Heinrich M.C., Corless C.L., Demetri G.D., Blanke C.D., von Mehren M., Joensuu H., McGreevey L.S., Chen C.J., Van den Abbeele A.D., Druker B.J., et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 21:2003;4342-4349. a
22. Heinrich M.C., Corless C.L., Duensing A., McGreevey L., Chen C.J., Joseph N., Singer S., Griffith D.J., Haley A., Town A., et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 299:2003;708-710. b
23. Hoque A., Sneige N., Sahin A.A., Menter D.G., Bacus J.W., Hortobagyi G.N., Lippman S.M. Her-2/neu gene amplification in ductal carcinoma in situ of the breast. Cancer Epi. Biomarkers Prev. 11:2002;587-590
24. Hruban R.H., Goggins M., Parsons J., Kern S.E. Progression model for pancreatic cancer. Clin. Cancer Res. 6:2000;2969-2972
25. Hsi L.C., Xi X., Lotan R., Shureiqi I., Lippman S.M. The histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells. Cancer Res. in press:2004
26. Hynes R.O. Metastatic potential. Generic predisposition of the primary tumor or rare, metastatic variants - or both? Cell. 113:2003;821-823
27. Izzo J.G., Papadimitrakopoulou V.A., Liu D.D., den Hollander P.L., Babenko I.M., Keck J., el-Naggar A.K., Shin D.M., Lee J.J., Hong W.K., Hittelman W.N. Cyclin D1 genotype, response to biochemoprevention, and progression rate to upper aerodigestive tract cancer. J. Natl. Cancer Inst. 95:2003;198-205
28. Khuri F.R., Nemunaitis J., Ganly I., Arseneau J., Tannock I.F., Romel L., Gore M., Ironside J., MacDougall R.H., Heise C., et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med. 6:2000;879-885
29. Koehne C.H., Dubois R.N. COX-2 inhibition and colorectal cancer. Semin. Oncol. 31:2004;12-21
30. Korn E.L. Nontoxicity endpoints in phase I trial designs for targeted, non-cytotoxic agents. J. Natl. Cancer Inst. 96:2004;977-978
31. Leong P.P., Rezai B., Koch W.M., Reed A., Eisele D., Lee D.J., Sidransky D., Jen J., Westra W.H. Distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma. J. Natl. Cancer Inst. 90:1998;972-977
32. Leyland-Jones B., Gelmon K., Ayoub J.P., Arnold A., Verma S., Dias R., Ghahramani P. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J. Clin. Oncol. 21:2003;3965-3971
33. Li D., Xie K., Wolff R., Abbruzzese J.L. Pancreatic cancer. Lancet. 363:2004;1049-1057
34. Lippman S.M., Brown P.H. Tamoxifen prevention of breast cancer. An instance of the fingerpost J. Natl. Cancer Inst. 91:1999;1809-1819
35. Lippman S.M., Hong W.K. Molecular markers of the risk of oral cancer. N. Engl. J. Med. 344:2001;1323-1326
36. Lippman S.M., Hong W.K. Cancer prevention science and practice. Cancer Res. 62:2002;5119-5125
37. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350:2004;2129-2139
38. Morgan B., Thomas A.L., Drevs J., Hennig J., Buchert M., Jivan A., Horsfield M.A., Mross K., Ball H.A., Lee L., et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases. Results from two phase I studies J. Clin. Oncol. 21:2003;3955-3964
39. Nugent K.P., Farmer K.C., Spigelman A.D., Williams C.B., Phillips R.K. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br. J. Surg. 80:1993;1618-1619
40. Nugent K.P., Spigelman A.D., Phillips R.K. Tissue prostaglandin levels in familial adenomatous polyposis patients treated with sulindac. Dis. Colon Rectum. 39:1996;659-662
41. O'Shaughnessy J.A., Kelloff G.J., Gordon G.B., Dannenberg A.J., Hong W.K., Fabian C.J., Sigman C.C., Bertagnolli M.M., Stratton S.P., Lam S., et al. Treatment and prevention of intraepithelial neoplasia. An important target for accelerated new agent development Clin. Cancer Res. 8:2002;314-346
42. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F.J., Lindeman N., Boggon T.J., et al. EGFR mutations in lung cancer. Correlation with clinical response to gefitinib therapy Science. 304:2004;1497-1500
43. Pai R., Soreghan B., Szabo I.L., Pavelka M., Baatar D., Tarnawski A.S. Prostaglandin E2 transactivates EGF receptor. A novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy Nat. Med. 8:2002;289-293
44. Parulekar W.R., Eisenhauer E.A. Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents. Theory and practice J. Natl. Cancer Inst. 96:2004;990-997
45. Rao P.S., Tian X., Qin W., Aruva M.R., Sauter E.R., Thakur M.L., Wickstrom E. 99mTc-peptide-peptide nucleic acid probes for imaging oncogene mRNAs in tumours. Nucleic Med. Commun. 24:2003;857-863
46. Rudin C.M., Cohen E.E., Papadimitrakopoulou V.A., Silverman S. Jr., Recant W., el-Naggar A.K., Stenson K., Lippman S.M., Hong W.K., Vokes E.E. An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. J. Clin. Oncol. 21:2003;4546-4552
47. Rusnak D.W., Lackey K., Affleck K., Wood E.R., Alligood K.J., Rhodes N., Keith B.R., Murray D.M., Knight W.B., Mullin R.J., et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol. Cancer Ther. 1:2001;85-94
48. Shpitz B., Klein E., Buklan G., Neufeld D., Nissan A., Freund H.R., Grankin M., Bernheim J. Suppressive effect of aspirin on aberrant crypt foci in patients with colorectal cancer. Gut. 52:2003;1598-1601
49. Shureiqi I., Jiang W., Fischer S.M., Xu X., Chen D., Lee J.J., Lotan R., Lippman S.M. GATA-6 transcriptional regulation of 15-lipoxygenase-1 during NSAID-induced apoptosis in colorectal cancer cells. Cancer Res. 62:2002;1178-1183
50. Shureiqi I., Jiang W., Zuo X., Wu Y., Stimmel J.B., Leesnitzer L.M., Morris J.S., Fan H.Z., Fischer S.M., Lippman S.M. The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPAR-delta to induce apoptosis in colorectal cancer cells. Proc. Natl. Acad. Sci. USA. 100:2003;9968-9973
51. Sinicrope F.A., Half E., Morris J.S., Lynch P.M., Morrow J.D., Levin B., Hawk E.T., Cohen D.S., Ayers G.D., Stephens L.C., Familial Adenomatous Polyposis Study Group Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients. Cancer Epidemiol. Biomarkers Prev. 13:2004;920-927
52. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer. Correlation of relapse and survival with amplification of the HER-2/neu oncogene Science. 235:1987;177-182
53. Spitz, M.R., Wu, X., and Mills, G. (2004). Integrative epidemiology: From risk assessment to outcome prediction. J. Clin. Oncol., in press.
54. Steinbach G., Lynch P.M., Phillips R.K., Wallace M.H., Hawk E., Gordon G.B., Wakabayashi N., Saunders B., Shen Y., Fujimura T., et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 342:2000;1946-1952
55. Sudbo J., Lippman S.M., Lee J.J., Mao L., Kildal W., Sudbo A., Sagen S., Bryne M., el-Naggar A., Risberg B., et al. The influence of resection and aneuploidy on mortality in oral leukoplakia. N. Engl. J. Med. 350:2004;1405-1413
56. Swain S.M., Wilson J.W., Mamounas E.P., Bryant J., Wickerham D.L., Fisher B., Paik S., Wolmark N. Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer. J. Natl. Cancer Inst. 96:2004;516-523
57. Takayama T., Katsuki S., Takahashi Y., Ohi M., Nojiri S., Sakamaki S., Kato J., Kogawa K., Miyake H., Niitsu Y. Aberrant crypt foci of the colon as precursors of adenoma and cancer. N. Engl. J. Med. 339:1998;1277-1284
58. Thompson I.M., Goodman P.J., Tangen C.M., Lucia M.S., Miller G.J., Ford L.G., Lieber M.M., Cespedes R.D., Atkins J.N., Lippman S.M., et al. The influence of finasteride on the development of prostate cancer. N. Engl. J. Med. 349:2003;215-224
59. Thun M.J., Henley S.J., Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents. Mechanistic, pharmacologic, and clinical issues J. Natl. Cancer Inst. 94:2002;252-266
60. Torrance C.J., Jackson P.E., Montgomery E., Kinzler K.W., Vogelstein B., Wissner A., Nunes M., Frost P., Discafani C.M. Combinatorial chemoprevention of intestinal neoplasia. Nat. Med. 6:2000;1024-1028
61. Tubbs R.R., Pettay J.D., Roche P.C., Stoler M.H., Jenkins R.B., Grogan T.M. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy. Apparent immunohistochemical false-positives do not get the message J. Clin. Oncol. 19:2001;2714-2721
62. Vogelstein B., Fearon E.R., Hamilton S.R., Kern S.E., Preisinger A.C., Leppert M., Nakamura Y., White R., Smits A.M., Bos J.L. Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 319:1988;525-532
63. Xiao Z., Luke B.T., Izmirlian G., Umar A., Lynch P.M., Phillips R.K., Patterson S., Conrads T.P., Veenstra T.D., Greenwald P., et al. Serum proteomic profiles suggest celecoxib-modulated targets and response predictors. Cancer Res. 64:2004;2904-2909